Omega-3 an Alzheimer’s flop
Fatty acid fails to slow decline in study participants
CHICAGO — Omega-3 pills promoted as memory boosters didn’t slow mental and physical decline in older patients with Alzheimer’s disease, a big disappointment in a multimillion-dollar government-funded study.
“We had high hopes that we’d see some efficacy, but we did not,’’ said Joseph Quinn, an author of the $10 million study and a researcher at Oregon Health and Science University.
The results with pills containing DHA, an omega-3 fatty acid, highlight “the continued frustration over lack of effective interventions’’ for the memory-robbing disease, said an editorial published with the study in today’s Journal of the American Medical Association. DHA occurs naturally in the brain and is found in reduced amounts in people with Alzheimer’s disease.
Some smaller, less rigorous studies suggested that mental decline could be slowed or prevented by eating fish, the main dietary source for omega-3 fatty acids, or by taking supplements like fish-oil pills that contain fatty acids including DHA. The study used capsules of DHA oil derived from algae.
Omega-3 fatty acids in fish or supplements have been shown to help protect against heart disease and are being studied for possible effects on a range of other illnesses including cancer and depression.
The new research involved nearly 300 men and women age 76 on average with mild to moderate Alzheimer’s disease. They were randomly assigned to take either DHA pills or dummy pills daily for 18 months. Results were similar in both groups; DHA provided no benefits in slowing Alzheimer’s symptoms. The pills also didn’t work even in a subgroup of participants with the mildest Alzheimer’s symptoms.
“There is no basis for recommending DHA supplementation for patients with Alzheimer disease,’’ the authors concluded.
Given evidence that the underlying process that causes Alzheimer’s begins years, if not decades, before diagnosis, starting treatment after symptoms appear may be too late, said editorial author Kristine Yaffe, a dementia researcher at University of California at San Francisco.
The National Institute on Aging paid for most of the research. The rest came from
Laurie Ryan, program director of Alzheimer’s studies at the Institute on Aging, called the results discouraging. But she noted that the institute is spending millions of dollars on research into other possible treatments including lifestyle changes, drugs, and biomarkers that might lead to more targeted drug treatment.